Page last updated: 2024-09-05

dofequidar and sdz psc 833

dofequidar has been researched along with sdz psc 833 in 8 studies

Compound Research Comparison

Studies
(dofequidar)
Trials
(dofequidar)
Recent Studies (post-2010)
(dofequidar)
Studies
(sdz psc 833)
Trials
(sdz psc 833)
Recent Studies (post-2010) (sdz psc 833)
40254555566

Protein Interaction Comparison

ProteinTaxonomydofequidar (IC50)sdz psc 833 (IC50)
ATP-dependent translocase ABCB1Homo sapiens (human)0.3969

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (37.50)18.2507
2000's5 (62.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tsuruo, T1
Naito, M; Tsuruo, T2
Ohno, R; Takeshita, A1
Aoki, J; Kimura, Y; Kohno, M; Nakanishi, O; Ooka, H; Tsuruo, T1
Kobayashi, M; Maekawa, M; Matsui, H; Naito, K; Ohnishi, K; Ohno, R; Shigeno, K; Shinjo, K; Takeshita, A; Tanimoto, M; Yamakawa, Y1
Hu, Y; Mizoi, K; Naitoh, Y; Sasajima, T; Satoh, T; Shimada, N; Takahashi, M1
Hirano, I; Kiyoi, H; Maekawa, M; Matsui, H; Nakamura, S; Naoe, T; Ohnishi, K; Ohno, R; Ono, T; Shigeno, K; Shinjo, K; Sugimoto, Y; Takeshita, A; Tobita, T; Yamakage, N1

Reviews

3 review(s) available for dofequidar and sdz psc 833

ArticleYear
[MDR reversing drugs for clinical development].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:7

    Topics: Animals; Antineoplastic Agents; Cyclosporins; Doxorubicin; Drug Resistance; Drug Synergism; Humans; Leukemia P388; Mice; Quinolines; Verapamil

1994
Therapeutic approach to drug resistant tumors.
    Therapeutic drug monitoring, 1998, Volume: 20, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Mitomycin; Quinolines

1998
[New combination therapies in hematological malignancies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cyclosporins; Cytarabine; Doxorubicin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, B-Cell; Myelodysplastic Syndromes; Prednisone; Quinolines; Rituximab; Tretinoin; Vidarabine; Vincristine

2000

Other Studies

5 other study(ies) available for dofequidar and sdz psc 833

ArticleYear
New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
    Cancer chemotherapy and pharmacology, 1997, Volume: 40 Suppl

    Topics: Animals; Antineoplastic Agents; Cell Division; Cyclosporins; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Quinolines; Tumor Cells, Cultured

1997
P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
    Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Cyclosporine; Cyclosporins; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Paclitaxel; Quinolines; Rats; Rats, Sprague-Dawley

2002
Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
    Leukemia, 2002, Volume: 16, Issue:5

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, CD34; Antigens, Differentiation, Myelomonocytic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cyclosporins; Drug Interactions; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Immunotoxins; Leukemia, Myeloid; Male; Middle Aged; Quinolines; Sialic Acid Binding Ig-like Lectin 3; Tumor Cells, Cultured

2002
(99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors.
    International journal of cancer, 2007, Dec-15, Volume: 121, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autoradiography; Brain Neoplasms; Carcinoma 256, Walker; Cell Line, Tumor; Cell Proliferation; Cyclosporine; Cyclosporins; Cytotoxins; Drug Resistance, Neoplasm; Drug Synergism; Predictive Value of Tests; Quinolines; Radiopharmaceuticals; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Vincristine

2007
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
    British journal of haematology, 2009, Volume: 146, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Count; Cell Line, Transformed; Cell Line, Tumor; Cyclosporins; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Immunosuppressive Agents; Inotuzumab Ozogamicin; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Quinolines; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Tumor Cells, Cultured

2009